

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 67811 86745

Express Mail Label Number

November 16, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

COLLINGWOOD ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/006795

FILED: 23 JUNE 2004

U.S. APPLICATION NO: 10/561,366

35 USC §371 DATE: 15 MAY 2006

FOR: PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS
FOR THE MUSCARINIC M3 RECEPTOR

MS: PCT

Commissioner for Patents

PO Box 1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists the **Applicant(s)** section and the "title". The city where the first and second inventors reside was incorrectly listed. The enclosed title page of the PCT International Publication Application No. WO 2005/000815 A3 shows the title change. Please issue a corrected filing receipt listing these sections as follows:

--Applicant(s)

Stephen Paul Collingwood, **West** Sussex, UNITED KINGDOM;
 Urs Baettig, **West** Sussex, UNITED KINGDOM
 Clive McCarthy, Basel, SWITZERLAND; --.

-- Title **Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor** --.

A copy of the filing receipt with the corrections noted is enclosed

No fee is believed to be required by this request for a corrected filing receipt.

Respectfully submitted,



 Gregory C. Houghton
 Attorney for Applicants
 Reg. No. 47,666

Novartis
 Corporate Intellectual Property
 One Health Plaza, Building 104
 East Hanover, NJ 07936-1080
 (862) 778-2614
 Enc.: copy of filing receipt
 copy of title page of WO 05/000816
 Date: November 16, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

GCH

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
PO Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/561,366	05/15/2006	1614	1030	PR/4-33239A		18	2

CONFIRMATION NO. 9747

1095
NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER, NJ 07936-1080

FILING RECEIPT



OC000000020366437

Date Mailed: 09/11/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Stephen Paul Collingwood, Sussex, UNITED KINGDOM;
Urs Baettig, Sussex, UNITED KINGDOM;
Clive McCarthy, Basel, SWITZERLAND;

Power of Attorney: The patent practitioners associated with Customer Number 1095.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP04/06795 06/23/2004 ✓

Foreign Applications

UNITED KINGDOM 0314697.4 06/24/2003

UNITED KINGDOM 0327526.0 11/26/2003 ✓

If Required, Foreign Filing License Granted: 09/08/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/561,366**

Projected Publication Date: 12/21/2006

Non-Publication Request: No

Early Publication Request: No



Title

PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS
LIGANDS FOR THE MUSCARINIC M3 RECEPTOR

Organic compounds

✓

Preliminary Class

424

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number
WO 2005/000815 A3

(51) International Patent Classification⁷: C07D 211/46, 207/08, 211/22, 409/14, A61K 31/40, 31/4025, 31/452, A61P 11/00

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(21) International Application Number:
PCT/EP2004/006795

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 23 June 2004 (23.06.2004)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(30) Priority Data:
0314697.4 24 June 2003 (24.06.2003) GB
0327526.0 26 November 2003 (26.11.2003) GB

(88) Date of publication of the international search report:
14 April 2005

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COLLINGWOOD, Stephen, Paul [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB (GB). BAETTIG, Urs [CH/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB (GB). MCCARTHY, Clive [GB/CH]; c/o Novartis AG, Lichtstrasse 35, CH-4056 Basel (CH).

WO 2005/000815 A3

(54) Title: PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS FOR THE MUSCARINIC M3 RECEPTOR



(57) Abstract: Compounds of formula (I) in salt or zwitterionic form wherein, wherein R¹, R², R³, R⁴, R⁵, J, L and M have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.